Hans Moebius
CIK 1822494 · View on SEC EDGAR ↗
First SEC filing: Sept. 17, 2020 · Latest: Sept. 17, 2020
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Nov. 15, 2022 | LONA | P | 5,000 | $3.29 | $16,450 | 65,836 Direct | +8.22% | Acquired | -74.8% (price as of 2026-08-19) |
| June 28, 2022 | LONA | P | 10,000 | $2.88 | $28,800 | 52,955 Direct | +23.28% | Acquired | -71.3% (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 2, 2023 | LONA | Stock Option (Right to Buy) | Common Stock (7,882) | $1.35 | Aug. 14, 2029 | 7,882 | Disposed |
| Jan. 19, 2023 | LONA | Stock Option (Right to Buy) | Common Stock (200,000) | $3.37 | Jan. 18, 2033 | 200,000 | Acquired |
| Oct. 13, 2022 | LONA | Stock Option (Right to Buy) | Common Stock (7,881) | $1.35 | Aug. 14, 2029 | 7,881 | Disposed |
| Jan. 18, 2022 | LONA | Stock Option (Right to Buy) | Common Stock (180,000) | $10.64 | Jan. 17, 2032 | 180,000 | Acquired |
| July 21, 2021 | LONA | Stock Option (Right to Buy) | Common Stock (15,762) | $1.35 | Aug. 14, 2029 | 15,762 | Disposed |
| July 21, 2021 | LONA | Stock Option (Right to Buy) | Common Stock (12,610) | $1.35 | June 25, 2029 | 12,610 | Disposed |
| Feb. 18, 2021 | LONA | Stock Option (Right to Buy) | Common Stock (72,000) | $21.15 | Feb. 17, 2031 | 72,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 3 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Sept. 17, 2020 | LONA | Stock Option (Right to Buy) [F1]→ Common Stock (12,610) | 12,610 | Direct |
| Sept. 17, 2020 | LONA | Stock Option (Right to Buy) [F1]→ Common Stock (31,525) | 31,525 | Direct |
| Sept. 17, 2020 | LONA | Stock Option (Right to Buy) [F1]→ Common Stock (145,015) | 145,015 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
LONA
M.D., Ph.DChief Medical Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2022 | $430,000 | — | — | $1,450,891 | $147,920 | — | $74,922 | $2,103,733 |
| 2020 | $218,859 | $190,220 | — | $593,430 | — | — | $15,979 | $1,018,488 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.